Cashen Amanda F, Nervi Bruno, DiPersio John
Washington University School of Medicine, Division of Oncology, 660 South Euclid Avenue, Campus Box 8007, St Louis, MO 63110, USA.
Future Oncol. 2007 Feb;3(1):19-27. doi: 10.2217/14796694.3.1.19.
As hematopoietic stem cells collected from peripheral blood are increasingly used for autologous and allogeneic stem cell transplantation, new approaches for the mobilization of stem cells are needed. These should have the goal of improving stem cell collection and reducing the duration and toxicity of the mobilization process. AMD3100, a specific inhibitor of CXCR4, one of the key molecules that tethers hematopoietic stem cells to the bone marrow microenvironment, is a promising new agent currently in clinical development for autologous and allogeneic stem cell mobilization. Early clinical trials have demonstrated that AMD3100 rapidly mobilizes stem cells to the peripheral blood, with minimal side effects. In Phase II trials, mobilization with the combination of AMD3100 and granulocyte colony-stimulating factor (G-CSF) results in the collection of more progenitor cells than G-CSF alone.
随着从外周血中采集的造血干细胞越来越多地用于自体和异基因干细胞移植，需要新的干细胞动员方法。这些方法应旨在改善干细胞采集，并缩短动员过程的持续时间和降低其毒性。AMD3100是CXCR4的一种特异性抑制剂，CXCR4是将造血干细胞 tether 到骨髓微环境的关键分子之一，是目前正在进行自体和异基因干细胞动员临床开发的一种有前景的新药。早期临床试验表明，AMD3100能迅速将干细胞动员到外周血，且副作用最小。在II期试验中，AMD3100与粒细胞集落刺激因子（G-CSF）联合动员比单独使用G-CSF能采集到更多的祖细胞。 （注：“tether”此处可能是“拴系、锚定”之类意思，但原文表述似乎有点不完整准确，不过按要求忠实翻译）
